ABSTRACT
In the adjuvant setting, tamoxifen is the established treatment for postmenopausal women with hormone-sensitive breast cancer. However, it is associated with several side-effects, including endometrial cancer and thromboembolic disorders. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial aimed to compare the safety and efficacy outcomes of tamoxifen with those of anastrozole (Arimidex) alone and the combination of anastrozole plus tamoxifen for 5 years.
